Eupraxia Pharmaceuticals Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
EPRX Nasdaq 2836 www.eupraxiapharma.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Eupraxia Pharmaceuticals Inc.

Eupraxia Pharmaceuticals Up 1.8% As Reports "Positive" Findings From Resolve Trial - Jan 8th, 2026 7:49 am
Eupraxia Pharmaceuticals Reports Positive Tissue Health Data from its Ongoing RESOLVE Trial in Eosinophilic Esophagitis Demonstrating Near-Complete Improvement on Biopsy - Jan 8th, 2026 5:34 am
Specific Biologics Welcomes Accomplished Biotechnology Leader Dr. Richard Glickman to its Board of Directors - Dec 16th, 2025 8:00 am
Analysts See More Than 77% Upside for Eupraxia Pharmaceuticals (EPRX), Here’s Why - Dec 4th, 2025 8:09 pm
Individual investors account for 43% of Eupraxia Pharmaceuticals Inc.'s (TSE:EPRX) ownership, while institutions account for 26% - Nov 17th, 2025 3:37 am
Wall Street Analysts Think Eupraxia Pharmaceuticals Inc. (EPRX) Could Surge 75.08%: Read This Before Placing a Bet - Nov 14th, 2025 7:55 am
Eupraxia Pharmaceuticals Reports Additional 52-week Follow-up Data from the RESOLVE Trial in Eosinophilic Esophagitis (EoE) Demonstrating Consistent Results after Dosing with EP-104GI - Nov 13th, 2025 3:00 pm
Eupraxia Pharmaceuticals Posts Wider Q3 Loss, Has Sufficient Cash on Hand To Fund It Into H1 2028 - Nov 4th, 2025 3:10 pm
Eupraxia Pharmaceuticals Reports Third Quarter 2025 Financial Results - Nov 4th, 2025 2:39 pm
Eupraxia Pharmaceuticals Inc. (EPRX) is a Great Momentum Stock: Should You Buy? - Oct 14th, 2025 10:00 am
Eupraxia Pharmaceuticals Inc. (EPRX) Upgraded to Buy: Here's Why - Oct 14th, 2025 10:00 am
Wall Street Analysts Believe Eupraxia Pharmaceuticals Inc. (EPRX) Could Rally 85.12%: Here's is How to Trade - Oct 14th, 2025 7:55 am
Eupraxia Pharmaceuticals Up 20% After Hours Following 'Positive' Data From Eosinophilic Esophagitis Trial - Sep 29th, 2025 3:29 pm
Eupraxia Pharmaceuticals Announces Positive Data from Highest-Dose Cohort in the Ongoing RESOLVE Trial in Eosinophilic Esophagitis, and Plans for Expansion of EP-104GI Development Programs - Sep 29th, 2025 3:00 pm
Independent Director of Eupraxia Pharmaceuticals Picks Up 13% More Stock - Sep 28th, 2025 6:58 am
Peterson Capital Hosts Canada Growth Conference in Ireland - Sep 25th, 2025 12:00 am
Eupraxia Raises US$80.5 Million in Public Offering to Fund Clinical Pipeline, Shares Slip 4% - Sep 24th, 2025 8:46 am
Eupraxia Pharmaceuticals Announces Closing of US$80.5 Million Public Offering Including Full Exercise of Underwriter Option - Sep 24th, 2025 6:54 am
Eupraxia Prices US$70M Share Offering at $5.50; U.S.-Listed Shares Fall 13% Pre-Market - Sep 23rd, 2025 5:14 am
Eupraxia Pharmaceuticals Announces Pricing of US$70 Million Public Offering of Common Shares - Sep 22nd, 2025 8:42 pm